⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL670254 | 0.77 | — | — | |
| SCHEMBL1660274 | 0.71 | — | — | |
| SCHEMBL4264660 | 0.71 | — | — | |
| SCHEMBL9419850 | 0.67 | TSHR (0.40) | — | |
| SCHEMBL19279597 | 0.62 | — | — | |
| SCHEMBL634990 | 0.62 | — | — | |
| SCHEMBL36501 | 0.62 | — | — | |
| SCHEMBL5464611 | 0.60 | — | — | |
| SCHEMBL6027208 | 0.60 | — | — | |
| SCHEMBL16346742 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12280196-B2 | Methods of using polymers | CYTOSORBENTS, INC. (US) | 2025-04-22 | — | — | US | claimed |
| US-20250009951-A1 | IMPROVED CANCER IMMUNOTHERAPY TREATMENTS | CYTOSORBENTS CORPORATION | 2025-01-09 | — | — | US | claimed |
| EP-3673930-B1 | BIOCOMPATIBLE SORBENT | CYTOSORBENTS CORP (US) | 2024-10-30 | — | — | EP | claimed |
| EP-4440657-A1 | IMPROVED CANCER IMMUNOTHERAPY TREATMENTS | Cytosorbents Corporation (US) | 2024-10-09 | — | — | EP | claimed |
| EP-4231986-B1 | PHOTOPROTECTIVE COMPOSITION | OREAL (FR) | 2024-10-09 | — | — | EP | claimed |
| CN-118613294-A | Improved cancer immunotherapy treatment | 西托索尔本茨公司 | 2024-09-06 | — | — | CN | claimed |
| US-12076474-B2 | Method of treating traumatic brain injury | CYTOSORBENTS, INC. (US) | 2024-09-03 | — | — | US | claimed |
| US-20240197977-A1 | IMPROVED IMMUNE RESPONSE AND DECREASED IMMUNOPARALYSIS WITH IMMUNOMODULATING TREATMENT | CYTOSORBENTS CORPORATION | 2024-06-20 | — | — | US | claimed |
| US-20230310493-A1 | REDUCTION OF ADVANCED GLYCATION ENDPRODUCTS FROM BODILY FLUIDS | AVENUE CAPITAL MANAGEMENT II, L.P. | 2023-10-05 | — | — | US | claimed |
| WO-2023097334-A1 | IMPROVED CANCER IMMUNOTHERAPY TREATMENTS | CYTOSORBENTS CORPORATION (US) | 2023-06-01 | — | — | WO | claimed |
| US-20120238441-A1 | Size-selective hemocompatible polymer system | AVENUE CAPITAL MANAGEMENT II, L.P. | 2012-09-20 | — | — | US | claimed |
| WO-2011123767-A1 | METHOD OF TREATING INFLAMMATION | CYTOSORBENTS CORPORATION (US) | 2011-10-06 | — | — | WO | claimed |
| US-7629049-B2 | Hemocompatible polymer systems and related devices | Medasorb, Inc. (US) | 2009-12-08 | — | — | US | claimed |
| US-20070160848-A1 | Hemocompatible polymer systems and related devices | AVENUE CAPITAL MANAGEMENT II, L.P. | 2007-07-12 | — | — | US | claimed |
| US-7201962-B2 | Hemocompatible coated polymer and related one-step methods | MEDASORB CORPORATION (US) | 2007-04-10 | — | — | US | claimed |
| US-7112620-B2 | Hemocompatible polymer systems & related methods | AVENUE CAPITAL MANAGEMENT II, L.P. | 2006-09-26 | — | — | US | claimed |
| US-20050159508-A1 | Hemocompatible coated polymer and related one-step methods | AVENUE CAPITAL MANAGEMENT II, L.P. | 2005-07-21 | — | — | US | claimed |
| WO-2005016976-A2 | HEMOCOMPATIBLE POLYMER SYSTEMS AND RELATED METHODS | ALBRIGHT ROBERT L (US) | 2005-02-24 | — | — | WO | claimed |
| US-20040076845-A1 | Hemocompatible polymer systems & related methods | AVENUE CAPITAL MANAGEMENT II, L.P. | 2004-04-22 | — | — | US | claimed |
| US-20040076827-A1 | Hemocompatible coated polymer and related one-step methods | AVENUE CAPITAL MANAGEMENT II, L.P. | 2004-04-22 | — | — | US | claimed |